Market Overview

Skystar Bio-Pharmaceutical Reports Q4 EPS of $0.55

Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) reported its Q4 diluted EPS at $0.55, versus the consensus of $0.57. SKBI reported its Q4 revenue at $15.8 million, versus the consensus of $14.91 million.

SKBI shares surged 10.04% to $6.03 in after-hours trading.

Read more from Benzinga's Company news.

Posted-In: EarningsEarnings News


Most Popular

Related Articles (SKBI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free